Effectiveness and Tolerability Profile of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes

被引：0
|
作者：
Gorgojo-Martinez, Juan J.
Feo-Ortega, Gara
Serrano-Moreno, Clara
Sanz-Velasco, Alberto
机构：
来源：
DIABETES | 2016年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2264-PUB
引用
收藏
页码：A573 / A573
页数：1
相关论文
共 50 条
  • [21] Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
    Margarita Capel
    Andreea Ciudin
    María Mareque
    Raquel María Rodríguez-Rincón
    Susana Simón
    Itziar Oyagüez
    PharmacoEconomics - Open, 2020, 4 : 277 - 286
  • [22] Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
    Capel, Margarita
    Ciudin, Andreea
    Mareque, Maria
    Maria Rodriguez-Rincon, Raquel
    Simon, Susana
    Oyaguez, Itziar
    PHARMACOECONOMICS-OPEN, 2020, 4 (02) : 277 - 286
  • [23] COST-EFFECTIVENESS ANALYSIS OF EXENATIDE VERSUS GLP-1 RECEPTOR AGONISTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Capel, M.
    Ciudin, A.
    Mareque, M.
    Rodriguez, R. M.
    Oyaguez, I
    VALUE IN HEALTH, 2018, 21 : S129 - S129
  • [24] EVALUATING THE COST-EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES IN THE UK
    Ashley, D.
    Vega, G.
    Hunt, B.
    Valentine, W. J.
    VALUE IN HEALTH, 2015, 18 (07) : A606 - A606
  • [25] GLP-1 Agonists: Improving the Future of Patients With Type 2 Diabetes
    Shubrook, Jay H.
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2011, 111 (02): : ESII - ES1
  • [26] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors Compared with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina M.
    Marsolo, Keith
    Bosworth, Hayden B.
    Pagidipati, Neha
    DIABETES, 2024, 73
  • [27] GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
    Neumiller, Joshua J.
    Alicic, Radica Z.
    Tuttle, Katherine R.
    KIDNEY AND DIALYSIS, 2022, 2 (03): : 386 - 398
  • [28] GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
    Marx, Nikolaus
    Husain, Mansoor
    Lehrke, Michael
    Verma, Subodh
    Sattar, Naveed
    CIRCULATION, 2022, 146 (24) : 1882 - 1894
  • [29] Diagnosed Nutritional Deficiencies Among Patients With Type 2 Diabetes on GLP-1 Receptor Agonists
    Butsch, W. Scott
    Kerr, Kirk
    Chang, Andrew
    Kim, Jeeyun
    Sulo, Suela
    Williams, Dominique
    Hegazi, Refaat
    Heymsfield, Steven
    OBESITY, 2024, 32 : 189 - 190
  • [30] Baseline Characteristics of Patients with Type 2 Diabetes Initiating Sitagliptin or GLP-1 Receptor Agonists
    Brodovicz, Kimberly G.
    Ritchey, Mary E.
    Chen, Yong
    Senderak, Michael
    Liao, Jane
    Girman, Cynthia J.
    Shankar, Ravi
    Liu, Zhiwen
    Engel, Samuel S.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 196 - 196
12345